Therapy News and Research

RSS

Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

The American Association for Cancer Research has chosen Prof. Alexander Levitzki of the Hebrew University of Jerusalem as the winner of its 2013 Award for Outstanding Achievement in Chemistry in Cancer Research.

9 Apr 2013

Certain brain tumors develop drug resistance by exploiting normal cellular signaling pathways

Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors.

9 Apr 2013

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that the Instituto de Salud Publica of Chile has approved the Company's protocol for its Phase 2 clinical study of TI-001, intranasal oxytocin, for the treatment of chronic migraine.

9 Apr 2013

Argentina's ANMAT approves AUBAGIO for patients with relapsing multiple sclerosis

Genzyme, a Sanofi company, announced today Argentina's National Administration of Drugs, Food and Medical Technology has approved once-daily, oral AUBAGIO 14 mg as a new treatment indicated for patients with relapsing forms of multiple sclerosis.

9 Apr 2013

Viewpoints: Drugging soldiers; GOP opposition to Medicaid expansion strays from party legacy; Health law distorts market

Last year, more active-duty soldiers committed suicide than died in battle. ... Worse, according to data not reported on until now, the military evidently responded to stress that afflicts soldiers in Iraq and Afghanistan primarily by drugging soldiers on the front lines.

9 Apr 2013

MIT researchers present novel approach to develop dengue therapy using mutated antibodies

Nearly half of the world's population is at risk of infection by the dengue virus, yet there is no specific treatment for the disease. Now a therapy to protect people from the virus could finally be a step closer, thanks to a team at MIT.

9 Apr 2013

Gilead Sciences submits sofosbuvir NDA to FDA for treatment of chronic HCV infection

Gilead Sciences today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration for approval of sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus infection.

9 Apr 2013

Study evaluates efficacy of drug combinations in treating colorectal cancer

Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Once colorectal cancer has spread to other parts of the body, only 11 percent of patients will survive five years from the date of their diagnosis.

8 Apr 2013

Antibody-guided drug shows promising activity in ovarian cancer patients with platinum drug-resistant disease

A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual meeting of the American Association for Cancer Research.

8 Apr 2013

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators will report at a special symposium of the American Association for Cancer Research annual meeting in Washington, April 6-10.

8 Apr 2013

Research: HIV women infected with HPV are not protected by current vaccines

Women with HIV acquire cancer-causing forms of the human papillomavirus (HPV) that are not included in the current HPV vaccines Gardasil and Cervarix, according to new research from Fox Chase Cancer Center being presented at the AACR Annual Meeting 2013 on Sunday, April 7.

8 Apr 2013

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

NewLink Genetics Corporation, a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American Association for Cancer Research 2013 annual meeting.

8 Apr 2013

FDA grants Breakthrough Therapy Designation for ibrutinib as monotherapy for CLL patients

Pharmacyclics, Inc. announced today that the U.S. Food and Drug Administration has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma patients with deletion of the short arm of chromosome 17 (deletion 17p).

8 Apr 2013

Lipocine announces favorable Phase I study results for LPCN 1111

Lipocine Inc., a biopharmaceutical company focused on developing innovative oral hormone therapies for men's and women's health, today announced favorable Phase I results for LPCN 1111.

8 Apr 2013

Phase 3 study results of simeprevir in hepatitis C patients to be presented at EASL Congress

Janssen R&D Ireland announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver, which will take place April 24 to 28 in Amsterdam, The Netherlands.

8 Apr 2013

GenSight Biologics announces closing of €32 million Series A financing

GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a €32 million Series A financing.

8 Apr 2013

FDA grants priority review for Bayer HealthCare's riociguat for treatment of CTEPH

Bayer HealthCare announced today that the New Drug Application for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration for the treatment of inoperable chronic thromboembolic pulmonary hypertension or with persistent or recurrent CTEPH after pulmonary endarterectomy and pulmonary arterial hypertension.

8 Apr 2013

Therapy News and Research

Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

Certain brain tumors develop drug resistance by exploiting normal cellular signaling pathways

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

Argentina's ANMAT approves AUBAGIO for patients with relapsing multiple sclerosis

Viewpoints: Drugging soldiers; GOP opposition to Medicaid expansion strays from party legacy; Health law distorts market

MIT researchers present novel approach to develop dengue therapy using mutated antibodies

Gilead Sciences submits sofosbuvir NDA to FDA for treatment of chronic HCV infection

Study evaluates efficacy of drug combinations in treating colorectal cancer

Antibody-guided drug shows promising activity in ovarian cancer patients with platinum drug-resistant disease

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

Research: HIV women infected with HPV are not protected by current vaccines

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

FDA grants Breakthrough Therapy Designation for ibrutinib as monotherapy for CLL patients

Lipocine announces favorable Phase I study results for LPCN 1111

Phase 3 study results of simeprevir in hepatitis C patients to be presented at EASL Congress

GenSight Biologics announces closing of €32 million Series A financing

FDA grants priority review for Bayer HealthCare's riociguat for treatment of CTEPH

Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting

Physician-researcher to lead pediatric Dream Team to create new treatments for childhood cancers

Dual-signaling CAR T cells show potent anti-cancer activity in animal model

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News